TY -的T1 pirfenidone对上气不接下气ness in patients with idiopathic pulmonary fibrosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00399-2019 VL - 54 IS - 3 SP - 1900399 AU - Glassberg, Marilyn K. AU - Wijsenbeek, Marlies S. AU - Gilberg, Frank AU - Petzinger, Ute AU - Kirchgaessler, Klaus-Uwe AU - Albera, Carlo Y1 - 2019/09/01 UR - //www.qdcxjkg.com/content/54/3/1900399.abstract N2 - Dyspnoea is a frequent and debilitating symptom in patients with idiopathic pulmonary fibrosis (IPF) and is reported as the most important factor determining their health-related quality of life (QoL) [1–3]. Previous post hoc analysis of pooled data from IPF clinical trials has shown that a worsening of dyspnoea was particularly likely in patients with more severe versus less severe disease [4]. Interestingly, it has been suggested that patients with more severe disease may experience a greater benefit from pirfenidone on categorical worsening of dyspnoea or death compared with patients with less severe disease [4]. Here, we report the results of a post hoc analysis aiming to further examine the effect of pirfenidone compared with placebo on dyspnoea severity in patients with IPF, including the change from baseline in dyspnoea over 12 months and categorical changes in dyspnoea at 12 months.New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVTMedical writing support was provided by Ceilidh McConnachie (CMC AFFINITY, a division of McCann Health Medical Communications Ltd, Glasgow, UK), funded by Genentech, Inc. and F. Hoffmann-La Roche, Ltd. ER -